MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/hon.2619

Медицинская библиотека · Hematological oncology · 2019

Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.

Palandri Francesca, Palumbo Giuseppe A, Abruzzese Elisabetta, Iurlo Alessandra, Polverelli Nicola, Elli Elena, Bonifacio Massimiliano, Bergamaschi Micaela, Martino Bruno, Tiribelli Mario, Benevolo Giulia, Tieghi Alessia, Sgherza Nicola, Isidori Alessandro, Binotto Gianni, Crugnola Monica, Heidel Florian, Cavazzini Francesco, Bosi Costanza, Auteri Giuseppe, Cattaneo Daniele, Foà Robin, Lemoli Roberto M, Cuneo Antonio, Krampera Mauro, Bartoletti Daniela, Cavo Michele, Vianelli Nicola, Breccia Massimo, Latagliata Roberto

Сравнительное исследованиеСтатьяПеревод пока не подготовлен

Аннотация

The 2016 WHO criteria identified early primary myelofibrosis (PMF) as an individual entity with milder clinical features and better outcome compared with overt PMF. Here, we compared early and overt PMF patients treated with ruxolitinib in terms of baseline clinical/laboratory characteristics, response, and toxicity to treatment. We observed that early-PMF patients achieve better and more stable spleen and symptoms responses, with significantly lower rates of hematological toxicities. No differences in overall and leukemia-free survival were detected between the two cohorts. The application of 2016 WHO criteria is crucial to identify those PMF patients who deserve a stricter monitoring during treatment.

Для цитирования: Palandri Francesca, Palumbo Giuseppe A, Abruzzese Elisabetta, Iurlo Alessandra, Polverelli Nicola, Elli Elena, Bonifacio Massimiliano, Bergamaschi Micaela, Martino Bruno, Tiribelli Mario, Benevolo Giulia, Tieghi Alessia, Sgherza Nicola, Isidori Alessandro, Binotto Gianni, Crugnola Monica, Heidel Florian, Cavazzini Francesco, Bosi Costanza, Auteri Giuseppe, Cattaneo Daniele, Foà Robin, Lemoli Roberto M, Cuneo Antonio, Krampera Mauro, Bartoletti Daniela, Cavo Michele, Vianelli Nicola, Breccia Massimo, Latagliata Roberto. Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.. Hematological oncology. 2019. DOI: 10.1002/hon.2619.

Предметные рубрики MeSH

AdolescentAdultAgedAged, 80 and overAntineoplastic AgentsClinical Laboratory TechniquesDiagnosis, DifferentialEarly DiagnosisFemaleHumansJanus Kinase 2MaleMiddle AgedMolecular Targeted TherapyNeoplasm ProteinsNitrilesOrgan SizePrimary MyelofibrosisProtein Kinase InhibitorsPyrazolesPyrimidinesRetrospective StudiesSpleenThrombocythemia, EssentialTreatment OutcomeWorld Health Organization
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.